Press "Enter" to skip to content

Cancer Therapy Tislelizumab Shows Early Efficacy Signs in Phase 2 Trial – Immuno-Oncology News

admin 0

Cancer Therapy Tislelizumab Shows Early Efficacy Signs in Phase 2 Trial  Immuno-Oncology News

BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, …

“liver cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *